United Therapeutics Corporation
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Material agreementSep 8 →Insiders1 insider bought $863,940 in 1 open-market buy. 12 insiders sold $1.04B, 1,764 of 1,775 sales on a 10b5-1 plan.→PeersClosest companies: AKBA, ALNY, LQDA→
From the filings
Figures
- Revenue
- $3.15Blast 12 months
- Net income
- $1.31Blast 12 months
- Operating cash flow
- $1.56Blast 12 months
- Cash and equivalents
- $1.80Bat the last balance sheet
- Shares outstanding
- 42.7M shareson issue